_

About the UKTS

A small charity doing BIG things…

UKTS’s overriding aim is to improve the lives of people living with thalassaemia.

 

We provide invaluable support to patients with the condition across the UK. This means supporting not only the patients and families themselves, but also a broader network of medical and educational professionals involved in their care. We organise conferences for health professionals to share information on latest treatments and support groups for patients to share their experiences.

We have given rise to a number of other charities around the world and continue to support them. We do not receive any government funding and are wholly dependent on private donations. It is vital that we continue fundraising in order to support all those – patients and their families, medical and educational professionals, overseas charities and many more – that are dependent on the work we do.

Our origins

The understanding of thalassaemia has come a long way since the early 20th century. Physicians and scientists began noticing patients with severe anaemia and enlarged spleens, which led to further study and observation. In the United Kingdom, researchers played a crucial role in unravelling the mysteries of thalassaemia.

Their efforts were focused on understanding the genetic basis of the disorder and developing effective treatments and management strategies. Through rigorous scientific investigations, it was discovered that thalassaemia was caused by inherited gene mutations that affected the production of haemoglobin.

During this time, the United Kingdom Thalassaemia Society (UKTS) was formed by a group of parents who came together to support each other as they watched their children face life-threatening health challenges. The creation of this society was a significant step forward in the fight against thalassaemia. The charity brought together patients, parents, health professionals, and researchers to collaborate on various aspects of the condition.

The main goals of UKTS were to improve the diagnosis, treatment, and support for individuals and families affected by thalassaemia. Over the years, the society has been at the forefront of advancements in thalassaemia research. UKTS have funded the development of innovative technologies such as the Desferal pump, which has greatly improved the administration of treatment. UKTS also funded the production of the first oral chelator deferiprone, which has made treatment more accessible for patients.

Additionally, we have supported research into MRI scans for monitoring heart and liver iron levels, as well as research in heart, liver, brain, bone health and gene therapies. These advancements have significantly enhanced the quality of life for thalassaemia patients.

In 2005, we published our first “Standards of the Clinical Care of Children and Adults Living with Thalassaemia in the UK,” which set the standard of care that every individual living with thalassaemia deserves. In 2023, we published the 4th Edition of these standards, reflecting their ongoing commitment to improving the lives of those affected by thalassaemia.

Overall, UKTS has played a vital role in the understanding, treatment, and support of individuals and families affected by thalassaemia. The dedication and contributions of members of the community over the years have made a significant impact on the lives of individuals living with thalassaemia patients and helping them lead healthier, happier and longer lives.